Failures and successes of clinical trials for Parkinson disease treatments

Retina

Volumn 25, Issue 8 SUPPL., 2005, Pages

  Dawson, Ted M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CEP 1345; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPA DECARBOXYLASE INHIBITOR; ENTACAPONE; ENZYME INHIBITOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GPI 1485; LEVODOPA; MINOCYCLINE; MIXED LINEAGE KINASE; MIXED LINEAGE KINASE INHIBITOR; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; TOCOPHEROL; TOLCAPONE; TRIHEXYPHENIDYL; UBIDECARENONE; UNCLASSIFIED DRUG;

BRAIN DEPTH STIMULATION; CLINICAL TRIAL; CONFERENCE PAPER; DEGENERATIVE DISEASE; DISEASE COURSE; DYSKINESIA; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; LIFESPAN; LONG TERM CARE; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PALLIDOTOMY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; RATING SCALE; RETINA DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; REVIEW;

CLINICAL TRIALS; HUMANS; PARKINSON DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33644873913     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200512001-00036     Document Type: Conference Paper

References (8)

1. Lim E. A walk through the management of Parkinson's disease. Ann Acad Med Singapore 2005;34:188-195.
2. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system (German). Klin Wochensch 1960;38:1236-1239.
3. Birkmayer W, Hornykiewicz O. The L-3,4-dioxyphenylalanine (L-DOPA)-effect in Parkinson-akinesia (German). Wien Klin Wochenschr 1961;73:787-788.
4. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of Parkinsonism. N Engl J Med 1967;276:374-379.
5. Smith AD, Zigmond MJ. Can the brain be protected through exercise? Lessons from an animal model of Parkinsonism. Exp Neurol 2003;184:31-39.
6. [No authors listed]. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
7. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of functional decline. Arch Neurol 2002;59:1541-1550.
8. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotropic factor in Parkinson disease. Nat Med 2003;9:589-595.